Monjuvi FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 9, 2020.
FDA Approved: Yes (First approved July 31, 2020)
Brand name: Monjuvi
Generic name: tafasitamab-cxix
Dosage form: for Injection
Company: MorphoSys AG
Treatment for: Diffuse Large B-Cell Lymphoma
Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Development timeline for Monjuvi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.